
What smart money is saying about Revvity, Inc.
2 funds in our archive have pitched Revvity, Inc., most recently EdgePoint Global Portfolio in June 2026.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2025 and Q3 2026, 8 fund letters reported a position in Revvity, Inc., with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 6 | 0 | 0 | 0 |
| Q2 2026 | 2 | 0 | 0 | 1 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 8 positions
- September 2026
“• Shares of life sciences and diagnostics company Revvity rose on growing optimism around a recovery in pharmaceutical research and development spending.”
Revvity, Inc. - September 2026
“• Shares of life sciences and diagnostics company Revvity rose on growing optimism around a recovery in pharmaceutical research and development spending.”
Revvity, Inc. - September 2026
“The portfolio’s strongest absolute returns this quarter were generated by the healthcare and energy sectors, both of which outperformed the comparable Russell 3000 sectors. The strategy’s healthcare sector was up +17% and soundly beat the Russell 3000 healthcare’s +6% return, courtesy of Revvity’s +38% third quarter gain.”
Revvity, Inc. - September 2026
Listed in Tributary Capital Management All Cap Equity Strategy’s reported holdings.
Revvity, Inc. - September 2026
“Integer Holdings Corporation, a medical device contract manufacturer, reported second quarter 2026 results above Street expectations. In addition, private equity firm KKR announced its intention to acquire Integer at $127 per share, representing an enterprise value of $5.8 billion and an implied next twelve months price-to-earnings multiple of 18.9x. Revvity, a medical technology company, reported above- consensus second quarter 2026 results, supported by PORTFOLIO MANAGERS: DONALD RADTKE & MARK WYNEGAR Tributary Capital Management, LLC clientservices@tributarycapital.com | 877.458.0021 | www.tributarycapital.com SMALL/MID CAP EQUITY MARKET COMMENTARY THIRD QUARTER 2026 11% diagnostics organic sales growth (excluding China) and meaningful operating profit margin expansion, driven by U.S. tariff refunds, volume growth and operational efficiencies.”
Revvity, Inc. - July 2026
“Positive performance in the quarter also came via good stock selection within the Health Care sector, with Jazz Pharmaceuticals up 27.5% and Revvity up 27.1%.”
Revvity, Inc. - June 2026
Listed in Guinness Global Quality Mid Cap Fund’s reported holdings.
Revvity, Inc. - June 2026
“As at June 30, 2026, Revvity, Inc. securities were held in EdgePoint Global Portfolio, EdgePoint Canadian Portfolio, EdgePoint Global Growth & Income Portfolio and EdgePoint Canadian Growth & Income Portfolio.”
Revvity, Inc.
Fund coverage · 2 theses
- EdgePoint Global PortfolioJune 2026
Revvity provides tools and services for drug discovery and diagnostics, with acquisitions improving growth and margins and AI potentially accelerating EPS growth.
Read the full thesis - Artisan U.S. Mid-Cap Value StrategyDecember 2025
Revvity Inc is a life sciences and diagnostics company with sticky, high-margin assets and stable diagnostics cash flows trading at a discount to peers.
Read the full thesis
Read every full thesis on Revvity, Inc.
Read all 2 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→